Hyperphosphatemia:治療薬パイプラインレビュー(2014年上半期)

◆英語タイトル:Hyperphosphatemia - Pipeline Review, H1 2014
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC4891IDB
◆発行日:2014年4月28日
◆調査対象地域:グローバル
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の市場調査資料のご購入、委託調査サービスに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[Hyperphosphatemia:治療薬パイプラインレビュー(2014年上半期)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Hyperphosphatemia – Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Hyperphosphatemia – Pipeline Review, H1 2014’, provides an overview of the Hyperphosphatemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hyperphosphatemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperphosphatemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyperphosphatemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hyperphosphatemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hyperphosphatemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hyperphosphatemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hyperphosphatemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hyperphosphatemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hyperphosphatemia Overview 7
Therapeutics Development 8
Pipeline Products for Hyperphosphatemia – Overview 8
Pipeline Products for Hyperphosphatemia – Comparative Analysis 9
Hyperphosphatemia – Therapeutics under Development by Companies 10
Hyperphosphatemia – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Hyperphosphatemia – Products under Development by Companies 15
Hyperphosphatemia – Companies Involved in Therapeutics Development 16
AstraZeneca PLC 16
Astellas Pharma Inc. 17
Mitsubishi Tanabe Pharma Corporation 18
OPKO Health, Inc. 19
Toray Industries, Inc. 20
Spectrum Pharmaceuticals, Inc. 21
Vifor Pharma AG 22
Medice Arzneimittel Putter GmbH & Co. KG 23
Hyperphosphatemia – Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 30
Drug Profiles 32
colestilan chloride – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
sucroferric oxyhydroxide – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
niacinamide – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SPI-014 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
tenapanor – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
colestilan chloride – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
PT-20 – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ASP-3325 – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
JPH-101 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
TRK-390 – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Hyperphosphatemia – Recent Pipeline Updates 47
Hyperphosphatemia – Dormant Projects 51
Hyperphosphatemia – Discontinued Products 52
Hyperphosphatemia – Product Development Milestones 53
Featured News & Press Releases 53
Mar 17, 2014: Keryx Biopharmaceuticals’ Zerenex Data Selected for Poster Presentation at the AMCP’s 26th Annual Meeting and Expo 53
Feb 12, 2014: Phosphate Therapeutics Selects Clinipace Worldwide to Manage its Phase 2 Renal Study 53
Nov 08, 2013: Keryx Biopharmaceuticals Provides Update From Ongoing Zerenex Long-Term Safety Extension Study in Patients With Hyperphosphatemia on Dialysis 53
Apr 15, 2013: Galenica Announces PDUFA Action Date For PA21 NDA 55
Mar 12, 2013: Vifor Pharma Submits Authorization Application For PA-21 In Switzerland 56
Jan 29, 2013: Mitsubishi Tanabe Pharma’s BindRen Receives Marketing Authorization In Europe For Treatment Of Hyperphosphatemia 56
Dec 20, 2012: Galenica Pharma Dispatches PA21 Dossier For Submission To European Medicines Agency 57
May 09, 2012: Keryx To Present Clinical Data Of Zerenex At National Kidney Foundation 2012 Spring Clinical Meetings 57
Apr 18, 2011: Keryx Starts Phase III Program Of Ferric Citrate In Japan By Partner, Japan Tobacco And Torii Pharmaceutical 58
Mar 14, 2011: Astellas Submits Application For Marketing Approval Of Bixalomer For Treatment Of Hyperphosphatemia In Japan 58
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 61
Disclaimer 61

List of Tables
Number of Products under Development for Hyperphosphatemia, H1 2014 8
Number of Products under Development for Hyperphosphatemia - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Hyperphosphatemia - Pipeline by AstraZeneca PLC, H1 2014 16
Hyperphosphatemia - Pipeline by Astellas Pharma Inc., H1 2014 17
Hyperphosphatemia - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 18
Hyperphosphatemia - Pipeline by OPKO Health, Inc., H1 2014 19
Hyperphosphatemia - Pipeline by Toray Industries, Inc., H1 2014 20
Hyperphosphatemia - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 21
Hyperphosphatemia - Pipeline by Vifor Pharma AG, H1 2014 22
Hyperphosphatemia - Pipeline by Medice Arzneimittel Putter GmbH & Co. KG, H1 2014 23
Assessment by Monotherapy Products, H1 2014 24
Number of Products by Stage and Target, H1 2014 26
Number of Products by Stage and Mechanism of Action, H1 2014 28
Number of Products by Stage and Route of Administration, H1 2014 29
Number of Products by Stage and Molecule Type, H1 2014 31
Hyperphosphatemia Therapeutics - Recent Pipeline Updates, H1 2014 47
Hyperphosphatemia - Dormant Projects, H1 2014 51
Hyperphosphatemia - Discontinued Products, H1 2014 52

List of Figures
Number of Products under Development for Hyperphosphatemia, H1 2014 8
Number of Products under Development for Hyperphosphatemia - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 13
Assessment by Monotherapy Products, H1 2014 24
Number of Products by Top 10 Target, H1 2014 25
Number of Products by Stage and Top 10 Target, H1 2014 26
Number of Products by Top 10 Mechanism of Action, H1 2014 27
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 28
Number of Products by Stage and Top 10 Route of Administration, H1 2014 29
Number of Products by Top 10 Molecule Type, H1 2014 30
Number of Products by Stage and Top 10 Molecule Type, H1 2014 31

*** 掲載企業 ***

AstraZeneca PLC
Astellas Pharma Inc.
Mitsubishi Tanabe Pharma Corporation
OPKO Health, Inc.
Toray Industries, Inc.
Spectrum Pharmaceuticals, Inc.
Vifor Pharma AG
Medice Arzneimittel Putter GmbH & Co. KG

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC4891IDB )"Hyperphosphatemia:治療薬パイプラインレビュー(2014年上半期)" (英文:Hyperphosphatemia - Pipeline Review, H1 2014)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。